- Home
- RSF vs CTSO Comparison
RSF vs CTSO Comparison
Compare RSF & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- CTSO
- Stock Information
- Founded
- RSF 2016
- CTSO 1997
- Country
- RSF United States
- CTSO United States
- Employees
- RSF N/A
- CTSO N/A
- Industry
- RSF Investment Managers
- CTSO Medical/Dental Instruments
- Sector
- RSF Finance
- CTSO Health Care
- Exchange
- RSF Nasdaq
- CTSO Nasdaq
- Market Cap
- RSF 62.5M
- CTSO 58.6M
- IPO Year
- RSF N/A
- CTSO N/A
- Fundamental
- Price
- RSF N/A
- CTSO $0.96
- Analyst Decision
- RSF
- CTSO Buy
- Analyst Count
- RSF 0
- CTSO 2
- Target Price
- RSF N/A
- CTSO $5.50
- AVG Volume (30 Days)
- RSF 11.8K
- CTSO 82.9K
- Earning Date
- RSF 01-01-0001
- CTSO 11-06-2025
- Dividend Yield
- RSF 10.61%
- CTSO N/A
- EPS Growth
- RSF N/A
- CTSO N/A
- EPS
- RSF N/A
- CTSO N/A
- Revenue
- RSF N/A
- CTSO $36,107,520.00
- Revenue This Year
- RSF N/A
- CTSO $11.93
- Revenue Next Year
- RSF N/A
- CTSO $21.22
- P/E Ratio
- RSF N/A
- CTSO N/A
- Revenue Growth
- RSF N/A
- CTSO 20.18
- 52 Week Low
- RSF $14.81
- CTSO $0.71
- 52 Week High
- RSF $16.23
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- RSF 51.11
- CTSO 50.38
- Support Level
- RSF $14.59
- CTSO $0.91
- Resistance Level
- RSF $14.89
- CTSO $1.02
- Average True Range (ATR)
- RSF 0.08
- CTSO 0.04
- MACD
- RSF 0.01
- CTSO 0.00
- Stochastic Oscillator
- RSF 52.86
- CTSO 49.58
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.